Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Consolidated Financial Results for the Three Months Ended June 30, 2026 [Under Japanese GAAP]

July 30, 2026
Tokyo Stock Exchange

Company name: KYORIN Pharmaceutical Co., Ltd.
Code number: 4569
Web site: https://www.kyorin-pharm.co.jp/
Representative: Yutaka Ogihara, Representative Director, President and Chief Executive Officer
Contact: Sakurou Banba, Director, Finance & Accounting
TEL (03) 6374-9704
Scheduled date to commence dividend payments: −
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: None

(Amounts rounded down to the nearest million yen)

1. Consolidated financial results for the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results

(Percentage indicate year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
June 30, 2026	29,654	−1.9	964	−59.3	1,241	−52.7	824	−60.8
June 30, 2025	30,229	6.4	2,368	106.0	2,624	85.1	2,100	137.1

(Note) Comprehensive income: For the three months ended June 30, 2026: 30 million yen (−98.5%),
For the three months ended June 30, 2025: 2,020 million yen (72.2%)

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2026	14.35	—
June 30, 2025	36.57	—

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
June 30, 2026	188,609	140,304	74.4
March 31, 2026	195,455	142,425	72.9

(Ref.) Equity: As of June 30, 2026 : 140,304 million yen,
As of March 31, 2026 : 142,425 million yen

2. Cash dividends

	Annual dividends per share				
(Record date)	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	—	20.00	—	37.00	57.00
Fiscal year ending March 31, 2027	—				
Fiscal year ending March 31, 2027 (Forecast)		10.00	—	15.00	25.00

(Note) Revisions to the forecast of cash dividend most recently announced: None

3. Forecast of consolidated for the year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentage indicate year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	57,800	−1.6	−300	—	−100	—	0	−100.0	0.00
Full year	121,800	−3.5	2,000	−43.9	2,300	−42.9	1,500	−56.5	26.11

(Note) Revisions to the forecast of consolidated most recently announced: None

4. Other

(1) Changes in significant subsidiaries during the period (Change in specified subsidiaries resulting in the scope of consolidation): None
Newly included: None, Excluded: None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements : Yes

(3) Changes in accounting policies, changes in accounting estimates and restatements
- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
- (ii) Changes in accounting policies due to other than (i): None
- (iii) Changes in accounting estimates: None
- (iv) Restatements: None

(4) Number of shares issued (common stock)
- (i) Number of issued shares at the end of the period (including treasury shares)
  - As of June 30, 2026 59,945,641 shares,
  - As of March 31, 2026 59,945,641 shares
- (ii) Number of treasury shares at the end of the period
  - As of June 30, 2026 2,499,370 shares,
  - As of March 31, 2026 2,499,346 shares
- (iii) Averaged number of shares outstanding during the period
  - Three months ended June 30, 2026 57,446,271 shares,
  - Three months ended June 30, 2025 57,448,849 shares

* This quarterly financial report is not subject to audit procedures by certified public accountants or audit firm.
* These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.
* Supplementary materials will be made available on the Company’s website in conjunction with the Summary of Consolidated Financial Results.